Literature DB >> 14559801

Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.

Pearlly S Yan1, Huidong Shi, Farahnaz Rahmatpanah, Timothy H-C Hsiau, Andrew H-A Hsiau, Yu-Wei Leu, Joseph C Liu, Tim Hui-Ming Huang.   

Abstract

Aberrant DNA methylation of promoter CpG islands is associated with transcriptionally repressive heterochromatin in neoplasia. The dynamics of this epigenetic process in mediating the transition from an active to an inactive state of transcription remains to be elucidated, however. Here, we used the methylation-specific oligonucleotide microarray to map the methylation patterns of a CpG island, located within the promoter and the first exon regions of RASSF1A, in normal breast tissue controls, primary tumors, and breast cancer cell lines. Oligonucleotide pairs, spaced along the CpG island region, were designed to discriminate between methylated and unmethylated alleles of selected sites. The methylation-specific oligonucleotide data indicate that the majority of test samples show widespread methylation in the first exon of RASSF1A. In contrast, the promoter area was usually undermethylated in normal controls and in 32% of the primary tumors tested, whereas the rest of the primary tumors and breast cancer cell lines showed various degrees of methylation in the region. Methylation profiling of individual tumors further suggest that DNA methylation progressively spreads from the first exon into the promoter area of this gene. Functional analysis indicates that increased density of RASSF1A promoter methylation is associated with altered chromatin, marked by a depletion of acetylated histones and methylated histone 3-lysine 4 and an enrichment of methylated histone 3-lysine 9 in the studied area. The combination of these epigenetic modifications may engender a stable silencing of the gene in breast cancer cells. Thus, this study underscores the importance of detailed mapping of methylation patterns within a CpG island locus that may provide insights into the progressive nature of aberrant DNA methylation and its relationship with transcriptional silencing during the neoplastic process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559801

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.

Authors:  Ashley G Rivenbark; Siobhan M O'Connor; William B Coleman
Journal:  Am J Pathol       Date:  2013-08-27       Impact factor: 4.307

Review 2.  Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases.

Authors:  Shuk-mei Ho; Wan-yee Tang
Journal:  Reprod Toxicol       Date:  2007-01-19       Impact factor: 3.143

3.  Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay.

Authors:  Yu-Wei Cheng; Carrie Shawber; Dan Notterman; Philip Paty; Francis Barany
Journal:  Genome Res       Date:  2005-12-20       Impact factor: 9.043

4.  Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats.

Authors:  Athena Starlard-Davenport; Volodymyr P Tryndyak; Smitha R James; Adam R Karpf; John R Latendresse; Frederick A Beland; Igor P Pogribny
Journal:  Carcinogenesis       Date:  2009-12-14       Impact factor: 4.944

5.  Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model.

Authors:  Scott C Borinstein; Melissa Conerly; Slavomir Dzieciatkowski; Swati Biswas; M Kay Washington; Patty Trobridge; Steve Henikoff; William M Grady
Journal:  Mol Carcinog       Date:  2010-01       Impact factor: 4.784

6.  Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry.

Authors:  Zhongfa Liu; Jiejun Wu; Zhiliang Xie; Shujun Liu; Patty Fan-Havard; Tim H-M Huang; Christoph Plass; Guido Marcucci; Kenneth K Chan
Journal:  Anal Biochem       Date:  2009-05-12       Impact factor: 3.365

Review 7.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

8.  Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.

Authors:  Teresita Muñoz-Antonia; Mariclara Torrellas-Ruiz; Jonathan Clavell; Linda A Mathews; Carlos A Muro-Cacho; Adriana Báez
Journal:  Int J Otolaryngol       Date:  2009-06-14

9.  Tackling the methylome: recent methodological advances in genome-wide methylation profiling.

Authors:  Marcos Rh Estécio; Jean-Pierre J Issa
Journal:  Genome Med       Date:  2009-11-16       Impact factor: 11.117

10.  Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.

Authors:  Aslaug Aa Muggerud; Jo Anders Rønneberg; Fredrik Wärnberg; Johan Botling; Florence Busato; Jovana Jovanovic; Hiroko Solvang; Ida Bukholm; Anne-Lise Børresen-Dale; Vessela N Kristensen; Therese Sørlie; Jörg Tost
Journal:  Breast Cancer Res       Date:  2010-01-07       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.